BBOT (BridgeBio Oncology Therapeutics) Research & Development: $140.37 Mil (TTM As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics Research & Development?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 Research & Development is $140.37 Mil as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. BridgeBio Oncology Therapeutics's Research & Development for the three months ended in Mar. 2026 was $39.80 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $140.37 Mil.

BridgeBio Oncology Therapeutics  (NAS:BBOT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BridgeBio Oncology Therapeutics Research & Development Related Terms

BridgeBio Oncology Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics Research & Development Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
56.29 73.11 121.20

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.64 27.44 35.05 38.07 39.80
BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $140.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $140.37 Mil mean?
BridgeBio Oncology Therapeutics (BBOT) has a Research & Development of $140.37 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' Research & Development too high?
BridgeBio Oncology Therapeutics' current Research & Development is $140.37 Mil. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' Research & Development compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' Research & Development of $140.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current Research & Development is $140.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current Research & Development of $140.37 Mil. The current Research & Development is $140.37 Mil. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current Research & Development is $140.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price